What Does Performance Status Mean for a Cancer Patient?

A patient’s performance status (performance status, PS) is an important concept in cancer care and treatment.

Below, 2 performance status scales used in cancer can be seen:

What Is a Cancer Patient’s Performance Status?

Performance status (PS) is one of the most central factors in cancer care. It plays a role in shaping prognosis (disease course) and determining the best treatment for a patient with cancer. Performance status is a score estimating a patient’s ability to perform certain daily living activities without help from others. These activities include basic tasks such as dressing, eating, and bathing, as well as more complex ones such as house cleaning and holding a regular job.

There are 2 commonly used performance status (PS) scales. The most widely used is called the Zubrod or ECOG (Eastern Cooperative Oncology Group) scale. It ranges from 0 to 4; “0” means fully functional and asymptomatic (without symptoms), while “4” means bedbound. Sometimes another scale, Karnofsky , is used. It ranges from 10 (near death) to 100 (no restrictions).

Why Is Performance Status Important in Cancer?

Many factors can predict how much cancer will affect a patient. Age, cancer stage, and other diseases all affect prognosis, but PS is one of the most important variables. It is even more important than age in predicting prognosis.

Patients with poorer PS and limited functional capacity tend to have more difficulty tolerating cancer treatments. Regardless of treatment, their outcomes are less favorable than those of patients with better PS.

Many clinical trials and the treatment recommendations derived from them are limited to fitter patients, such as those with ECOG PS 0 to 1 or a Karnofsky score above 70. Consequently, there is less clinical evidence for treatments in patients with low PS. Because almost all anticancer treatments can have serious adverse effects, the risks of certain treatments in low-PS patients may greatly outweigh benefits. However, other trials testing less intensive approaches may specifically allow or even focus on frailer patients needing more support.

Performance status usually changes over time. As cancer progresses, PS may gradually worsen because of the cancer itself and cumulative treatment adverse effects. Conversely, if the patient has cancer-related symptoms, effective treatment can improve performance status. 

Related Topic

Chemotherapy or Palliative Care: How Should the Decision Be Made?